Non-Small Cell Lung Cancer Conference Coverage

News

Impact of Care Delays on Health Care Resource Utilization in Patients With Early-Stage Lung Cancer

06/26/2024

Brandon Twyford

Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...

Researchers conducted a study on...

06/26/2024

Journal of Clinical Pathways

Conference Coverage

Subcutaneous vs Intravenous Amivantamab Plus Lazertinib for Patients With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer

06/01/2024

Natasha Leighl, MD

Natasha Leighl, MD, discussed results from the phase 3 PALOMA-3 trial which compared subcutaneous and intravenous amivantamab plus lazertinib in patients with advanced, EGFR-mutated non-small cell lung cancer.

Natasha Leighl, MD, discussed...

06/01/2024

Oncology

Conference Coverage

Should Docetaxel Plus Ramucirumab Be the Standard Second-Line Option for Patients With Non-Small Cell Lung Cancer?

05/15/2024

Edward Garon, MD

At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Edward Garon, MD, MS, argued that docetaxel plus ramucirumab should be the standard second-line option for patients with NSCLC.

At the Great Debates and Updates...

05/15/2024

Oncology

Conference Coverage

Non-Surgical Interventions for Patients With Stage 3 Non-Small Cell Lung Cancer

04/27/2024

Featuring Charles Simone, MD

At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Charles Simone, MD, argued that surgical approaches have a limited role in the treatment of patients with stage 3 non-small cell lung cancer.

At the Great Debates and Updates...

04/27/2024

Oncology

News

Tracking Cost of Care Discussions Between Physicians and Patients with NSCLC and Melanoma

10/30/2023

Grace Taylor , MS, MA;

Robin Yabroff, PhD, MBA, and Michael T. Halpern, MD, PhD, MPH, examine the documentation of cost of care discussions between physicians and patients with non–small cell lung cancer and melanoma.

Robin Yabroff, PhD, MBA, and...

10/30/2023

Journal of Clinical Pathways

News

New Dimensions in Comprehensive Genomic Testing

10/17/2023

Grace Taylor , MS, MA;

Eric Severson, MD, PhD, Labcorp Oncology, examines genomic testing’s role in comprehensive oncology pathways.

Eric Severson, MD, PhD, Labcorp...

10/17/2023

Journal of Clinical Pathways

Conference Coverage

Research Shows that Health Care Costs Vary Based on HIC Status in Patients With NSCLC

06/13/2023

Emry Lloyd ;

In an abstract presented at ASCO 2023, researchers compared real-world data on health care costs for HIC-H and HIC-C patients with NSCLC before and after they received the HIC test.

In an abstract presented at ASCO...

06/13/2023

Journal of Clinical Pathways

Conference Coverage

Inequities in Next-Generation Sequencing Testing Among Patients With Advanced Non–Small Cell Lung Cancer

06/07/2023

Dr Gregory Vidal, Breast Medical Oncologist, West Cancer Center, Germantown, TN, spoke with the Journal of Clinical Pathways at the ASCO 2023 Annual Meeting about his study on inequities in next-generation sequencing testing by race/ethnicity...

Dr Gregory Vidal, Breast Medical...

06/07/2023

Journal of Clinical Pathways

Conference Coverage

Cost-Effectiveness of Adjuvant Osimertinib vs Placebo in NSCLC

06/02/2021

Study findings suggest adjuvant osimertinib is more cost-effective than placebo if one is willing to pay $317,119 more per QALY gained.

Study findings suggest adjuvant...

06/02/2021

Journal of Clinical Pathways

Conference Coverage

Treatment Patterns After EGFR-TKI and Platinum-Based Chemotherapy Discontinuation in Metastatic NSCLC

04/16/2021

Study results show that immunotherapy is the most common next line of therapy after discontinuation of an EGFR-TKI and platinum-based chemotherapy for metastatic NSCLC.

Study results show that...

04/16/2021

Journal of Clinical Pathways

Current Issue

October 2024

Volume 10

Issue 5

Current Issue

Issue Archive

Special Reports

Sponsored

JCP Special Report

The Value of Tissue-Based Genomic Profiling in Oncology

09/17/2024

Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.

Innovations in precision...

09/17/2024

Journal of Clinical Pathways

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee ;

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Robin T. Zon , MD, FACP, FASCO;

Gordon Kuntz ;

Winston Wong , PharmD;

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan ;

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Non-Small Cell Lung Cancer Conference Coverage

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products